2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-121155
    AD11 74670-75-0
    AD11, a sulfonamide derivative, exhibits anticonvulsant potency in the rat.
    AD11
  • HY-121164
    GSK172981 1133705-99-3 98%
    GSK172981 is a brain-penetrant tachykinin NK3 receptor antagonist with pKi values of 7.7 and 7.8 for human and native guinea pig NK3 receptors, respectively. GSK172981 can be used for the study of schizophrenia.
    GSK172981
  • HY-121191
    Bisnorcymserine 219920-81-7 98%
    Bisnorcymserine ((-)-Bisnorcymserine) is an inhibitor for butyrylcholinesterase (BChE) with an IC50 of 0.228 nM. Bisnorcymserine reduces the levels of amyloid-β peptide (Aβ), exhibits ameliorates the Alzheimer’s Disease in elderly rat models. Bisnorcymserine is blood-brain barrier penetrate.
    Bisnorcymserine
  • HY-12119B
    GW274150 dihydrochloride 438542-17-7 98%
    GW274150 (dihydrochloride) is a potent, selective, orally active and NADPH-dependent inhibitor of human inducible nitric oxide synthase (iNOS) (IC50=2.19 μM; Kd=40 nM) and rat iNOS (ED50=1.15 μM). GW274150 (dihydrochloride) displays less potency for both humans or rats endothelial NOS (eNOS) and neuronal NOS (nNOS). GW274150 (dihydrochloride) exerts a protective role in an acute model of lung injury inflammation.
    GW274150 dihydrochloride
  • HY-121215
    Chloracyzine 800-22-6 98%
    Chloracyzine is an antianginal agent with spasmolytic properties and prevent or relieve spasms of the coronary vessels. Chloracyzine shows a moderate antihistaminic effect.
    Chloracyzine
  • HY-121239
    Lemnalol 82570-34-1 98%
    Lemnalol is a potent agent for neuropathic pain. Lemnalol possesses potent anti-inflammatory, analgesic and anti-tumor activities. Lemnalol has the capacity to attenuate hyperalgesia and allodynia by modulation of neuroinflammatory processes in neuropathy. Lemnalol modulates LPS-induced alterations of left atrial (LA) calcium homeostasis and blocks the NF-κB pathways, which may contribute to the attenuation of lipopolysaccharide (LPS)-induced arrhythmogenesis and neuropathic pain. Lemnalolis a ylangene-type sesquiterpenoid compound, isolated from Lemnalia cervicorni.
    Lemnalol
  • HY-121249
    Capeserod hydrochloride 191023-43-5 98%
    Capeserod hydrochloride (SL65.0155) is a 5-HT4(e) receptor partial agonist (Ki=0.6 nM) with potent cognitive enhancing properties. Capeserod hydrochloride acts as a partial agonist in cells expressing 5-HT4(b) and 5-HT4(e) splice variants, stimulating cAMP production with IC50 values of 244 and 29 nM, respectively. Capeserod hydrochloride is used in the study of memory impairment and dementia.
    Capeserod hydrochloride
  • HY-121275
    Benserazide 322-35-0 98%
    Benserazide is an aromatic L-amino acid decarboxylase (AADC) and L-DOPA decarboxylase inhibitor. Benserazide is also a PKM2 inhibitor. Benserazide directly binds to and blocks PKM2 enzyme activity, leading to inhibition of aerobic glycolysis concurrent up-regulation of OXPHOS. Benserazide can be used for the study of Parkinson's disease and melanoma.
    Benserazide
  • HY-121299
    m-Chlorophenylbiguanide 48144-44-1
    m-Chlorophenylbiguanide (mCPBG) is a potent high-affinity agonist of the 5-HT3 receptor, exhibiting an inhibitory effect on long-term potentiation (LTP) in the mossy fiber-CA3 system. mCPBG attenuates the magnitude of LTP at concentrations of 0.3-1 microM, demonstrating its role in modulating synaptic plasticity. Additionally, the impact of mCPBG on LTP is reversible by the GABAA receptor antagonist bicuculline, indicating a connection between its action and GABAergic neurotransmission.
    m-Chlorophenylbiguanide
  • HY-121306
    Indecainide 74517-78-5 98%
    Indecainide (Ricainide) is an orally active antiarrhythmic agent. Indecainide can be used in the research of ventricular dysfunction. Indecainide has Na+-channel-blocking activity.
    Indecainide
  • HY-121313
    Embusartan 156001-18-2 98%
    Embusartan (BAY 10-6734) is a brain-penetrant and effective AT1 receptor blocker. Embusartan inhibits Ang II binding to brain AT1 receptors in the nuclei of central nervous system (CNS) inside due to high lipophilic character. Embusartan is promising for research of sympathetic hyperactivity and hypertension.
    Embusartan
  • HY-121318
    LK 11 74143-01-4 98%
    LK-11 is a tropane derivative that inhibits the passive uptake of noradrenalin (NA) by hypothalamic synaptic vesicles in vitro, similar to cocaine.
    LK 11
  • HY-121328
    Empenthrin 54406-48-3 98%
    Empenthrin (S-2852F) is a synthetic pyrethroid. Empenthrin can be used in insecticides. Empenthrin shows a clear species-specificity in the inhibitory effect on the Pentobarbital (PTB)-metabolizing enzyme(s). Empenthrin prolongs PTB induced-sleeping time in mice through an inhibition of the PTB-metabolizing enzyme(s) in the liver, an effect that does not occur in rats. Empenthrin shows a clear species-specificity in the inhibitory effect on the PTB-metabolizing enzyme(s).
    Empenthrin
  • HY-121333
    Dinactin 20261-85-2 98%
    Dinactin, an antibiotic ionophore produced by Streptomyces species, as an effective small molecule targeting Wnt/β-catenin signaling pathway in cancer cells. Dinactin shows marked inhibition of HCT-116 cell growth with an IC50 of 1.1 μM. Dinactin shows anti-proliferative activity against the cancer cells in apoptosis-independent manner. Dinactin is also an effective agent for the research of neuropathic pain.
    Dinactin
  • HY-121340
    Emylcamate 78-28-4 98%
    Emylcamate is a potent muscle relaxant. Emylcamate has the potential for the research of neurological diseases.
    Emylcamate
  • HY-121345
    Homobaldrinal 67910-07-0 98%
    Homobaldrinal is a decomposition product of Valepotriate (HY-N0718). Homobaldrinal exhibits genotoxic activity in the Salmonella/microsome test.
    Homobaldrinal
  • HY-121404
    Muscarine 300-54-9 98%
    Muscarine ((+)-Muscarine) is an agonist of prototype mAChR. Muscarine is a toxin that can stimulate the parasympathetic nervous system.
    Muscarine
  • HY-121415
    Herkinorin 862073-77-6 98%
    Herkinorin is a potent and selective agonist of µ opioid receptor with a Ki of 45 nM Herkinorin is widely used for pain research.
    Herkinorin
  • HY-121436
    Levoxadrol 4792-18-1 98%
    Levoxadrol is an active enantiomer of dexoxadrol.
    Levoxadrol
  • HY-121500
    R-116010 355860-40-1 98%
    R-116010 is a potent and selective retinoic acid (RA) metabolism inhibitor and can inhibit hydroxylase CYP26. R-116010 can enhance the anti-tumor effect of retinoic acid drugs. R-116010 can be used for the research of cancer, metabolic and neurological disease, such as neuroblastoma.
    R-116010
Cat. No. Product Name / Synonyms Application Reactivity